Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets

Rhea-AI Summary

Evotec SE announced that Bayer has discontinued the development of eliapixant (BAY1817080), an investigational P2X3 receptor antagonist. Bayer determined that the risks outweigh the benefits after reviewing the available data. As a result, Evotec regains rights to all P2X3 assets and will evaluate the data and options moving forward. The company states that this change does not affect its strategic goals outlined in the Action Plan 2025.

Positive

• Evotec regains rights to all P2X3 assets.
• Company will evaluate data and future options.

Negative

• Bayer's decision indicates potential challenges with eliapixant's efficacy or safety.
• Development discontinuation may reflect adversely on investor confidence.

HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.

Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.

As a consequence of Bayer's decision, Evotec regains the rights to all P2X3 assets. The Company will evaluate the underlying data as soon as they are made available and will evaluate all options.

This decision has no impact on the overall strategic goals as outlined in Action Plan 2025.

Contact:

Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7, 22419 Hamburg, Germany
Phone: +49.(0)40.560 81-242
werner.lanthaler@evotec.com

SOURCE: Evotec AG

View source version on accesswire.com:
https://www.accesswire.com/687278/Bayer-Discontinues-Clinical-Development-Candidate-Eliapixant-BAY1817080-Evotec-Regains-the-Rights-to-all-P2X3-Assets

FAQ

What happened to eliapixant (BAY1817080)?

Bayer discontinued the development of eliapixant due to safety risks outweighing benefits.

How does Bayer's decision affect Evotec?

Evotec regains rights to all P2X3 assets and will assess the available data.

What is Evotec's next step after regaining P2X3 rights?

The company plans to evaluate data and explore future options.

Does this decision impact Evotec's strategic goals?

Evotec confirmed that the decision has no impact on its Action Plan 2025.